Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.72 |
| ▸ | GSK3B | P49841 | 5/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.72 |
| ▸ | SRC | P12931 | 3/20 | 0.72 |
| ▸ | GSK3A | P49840 | 3/20 | 0.72 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.57 |
| ▸ | SPAST | Q9UBP0 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073913 | 0.84 | SPAST (0.58) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL29435815 | 0.84 | AURKA (1.00) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL462877 | 0.84 | AURKA (1.00) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL801474 | 0.83 | CYP1A2 (0.63) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL786449 | 0.79 | GSK3B (0.60) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL24022423 | 0.78 | AURKA (0.88) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL3998184 | 0.77 | SRC (0.80) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL16941178 | 0.77 | AURKA (0.75) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL802191 | 0.77 | AURKA (1.00) | AURKAGSK3BAURKBSRCGSK3A | |
| SCHEMBL3993717 | 0.77 | AURKA (0.66) | AURKAGSK3BAURKBSRCGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638926-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-28 | — | — | US | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885GSK3B 3/4885AURKB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.